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Abstract 
Catheter ablation may reduce ventricular tachycardia (VT) burden in arrhythmogenic right 
ventricular cardiomyopathy (ARVC) patients. However, little is known about factors predicting 
need for ablation. Therefore, we sought to investigate predictors and use of VT ablation and to 
evaluate the post-procedural outcome in ARVC patients. We studied 435 patients from the Nordic 
ARVC registry including 220 probands with definite ARVC according to the 2010 task force 
criteria and 215 mutation-carrying relatives identified through cascade screening. Patients were 
followed until first-time VT ablation, death, heart transplantation, or January 1st 2018. 
Additionally, patients undergoing VT ablation were further followed from the time of ablation for 
recurrent ventricular arrhythmias. The cumulative use of VT ablation was 4% (95%CI 3%-6%) and 
11% (95%CI 8%-15%) after 1 and 10 years. All procedures were performed in probands in whom 
cumulative use was 8% (95%CI 5%-12%) and 20% (95%CI 15%-26%). In adjusted analyses 
among probands, only young age predicted ablation. In patients undergoing ablation, risk of 
recurrent arrhythmias was 59% (95%CI 44%-71%) and 74% (95%CI 59%-84%) 1 and 5 years after 
the procedure. Despite high recurrence rates, the burden of ventricular arrhythmias was reduced 
after ablation (p=0.0042). Young age, use of several antiarrhythmic drugs and inducibility to VT 
after ablation were associated with an unfavorable outcome. In conclusion, twenty percent of 
ARVC probands developed a clinical indication for VT ablation within 10 years whereas mutation-
carrying relatives were without such need. Although the burden of ventricular arrhythmias 
decreased after ablation, risk of recurrence was substantial. 
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Current guidelines recommend implantable cardioverter defibrillator (ICD) implantation as first-
line therapy for the treatment of ventricular tachycardia (VT) in arrhythmogenic right ventricular 
cardiomyopathy (ARVC) patients at intermediate or high risk of future ventricular arrhythmias.1 
Severely affected patients with incessant VT or frequent appropriate ICD interventions on 
maximally tolerated antiarrhythmic drugs (AAD) therapy may also be candidates for VT catheter 
ablation.1 Recently, a risk calculator to predict first-time episodes of ventricular arrhythmias in 
ARVC patients has been developed.2 However, there have been no studies reporting the risk of a 
need for VT ablation in ARVC patients. Consequently, it is unclear what characterizes the subgroup 
of patients at increased risk of developing a severe disease state requiring ablation. Moreover, 
several studies have reported varying results on the procedural efficacy.3-12 These studies have 
predominantly been conducted at large referral centers specialized in VT ablation and therefore the 
results may not reflect the general effect of VT ablation due to the selection and high volume in 
these centers. Therefore, the purpose of this study was to evaluate predictors and use of VT ablation 
and the post-procedural long-term outcome in a large multicenter cohort of patients with ARVC. 
Methods 
We conducted an observational cohort study using the Nordic ARVC Registry. The registry 
contains data on ARVC patients from eight institutions specialized in inherited cardiac diseases 
across Denmark, Norway, and Sweden (covering a population of approximately 14 million 
inhabitants). Patients with ARVC according to the 1994 Task Force Criteria (TFC)13 were 
retrospectively included in the registry when it was launched in June 2010, and since then patients 
fulfilling the 2010 TFC14 have prospectively been included. For the present study we included 
patients (comprising both probands and relatives) in the registry fulfilling a diagnosis of definite 
ARVC according to the 2010 TFC.14 Genetic variants were classified according to the guidelines in 
force at the time of inclusion. In case a pathogenic mutation was found in the proband we also 
included mutation-carrying relatives identified through cascade screening following the mutation as 
far as possible in the respective families. These relatives were included irrespective of the TFC 
criteria, because we considered asymptomatic mutation-carriers to be in a subclinical disease state 
at risk of a need for future VT ablation. We followed all patients from the time of inclusion until the 
event of interest, death, heart transplantation, or January 1st 2018, whichever came first. In 
Denmark, registry studies do not require approval from an ethics committee, but approval was 
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obtained from the Danish Data Protection Agency. The study complies with the Declaration of 
Helsinki. 
Baseline clinical characteristics, data specific for the ARVC diagnosis as well as 
ventricular arrhythmic events and medical interventions are pre-specified registry variables. These 
data have prospectively been entered into the database upon clinical contacts according to the 
registry protocol since 2010. Historical information prior to the launch of the database has been 
entered based on information from the patients’ medical records. Follow-up was performed 
regularly in all patients. In our centers, patients with definite ARVC are followed with symptom-
driven examinations and seen at least annually.15 For the present study we extracted information on 
changes in AADs (including amiodarone, beta-blockers, sotalol, and other AADs) as well as data on 
ICD implantation and VT ablation, which are pre-specified reportable clinical events in the registry. 
The team of cardiac electrophysiologists at each site made the treatment indications including 
indications to perform VT ablation. VT ablations were performed using electro-anatomical mapping 
from 1998 and with the implementation of thermo-cool catheters from 2000 and onwards. VT 
ablation procedures were categorized as successful or unsuccessful depending on whether VT could 
be induced on repeated programmed ventricular stimulation immediately after the ablation 
procedure. Additional details regarding procedural access (i.e. endocardial, epicardial, or combined 
VT ablation procedure) and procedural complications were requested from each of the participating 
sites and collected from the medical records. We further retrieved events of sustained VT, 
ventricular fibrillation (VF), electrical storms defined as cases of three or more episodes of 
sustained VT/VF or appropriate ICD therapy per day, death (including causes of death), and heart 
transplantation. All episodes of VT/VF were documented by electrocardiogram- and/or ICD 
recordings. 
Data are presented as mean ± standard deviation (SD), median (interquartile range 
(IQR)) or number (proportion). Differences in baseline characteristics were evaluated using 
Wilcoxon’s rank sum test, chi square test, or Fisher’s exact as appropriate. We calculated the 
cumulative incidence of first-time VT ablation after 1, 5 and 10 years accounting for death and 
heart transplantation as competing risks.16 Cox proportional hazards regression was used to 
calculate unadjusted and adjusted hazard ratios (HRs) for potential predictors (age above median of 
38 years, sex, proband status, sustained VT or aborted SCD at presentation, and mutation status) of 
first-time VT ablation. Probability weights were used to account for possible family clustering 
effects (except for analyses, which only included probands). The proportional hazards assumption 
was tested using log-log plots and found to be valid in all cases except for proband status since all 
events were observed among probands and none among relatives. Therefore, we restricted adjusted 
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analyses to probands in which the remaining four predefined variables were included as covariates. 
All covariates were simultaneously added to the model. Since Cox regression was not a valid 
method to specifically address the difference in likelihood of VT ablation between probands and 
relatives we used a permutation test on the basis of 100.000 Monte Carlo simulations with matching 
based on age and sex to obtain a valid p-value. To evaluate the risk of recurrent arrhythmias as well 
as predictors of a favorable outcome after VT ablation we calculated the cumulative incidence of a 
composite endpoint of recurrent ventricular arrhythmias (appropriate ICD therapy, documented 
sustained VT or VF, electrical storm, aborted SCD, and SCD) after VT ablation at 1 and 5 years. 
Non- cardiac death, and heart transplantation were considered competing risks. Cox regression 
models with pre-specified subgroups (age above median at time of ablation, sex, number of AADs, 
endocardial- vs. epicardial or combined procedure, and immediate success after VT ablation) were 
used to evaluate potential predictors of a favorable outcome. Additionally, in a subgroup of patients 
with follow-up available 6 months before and after the ablation procedure, we investigated the 
registered burden of ventricular arrhythmias (appropriate ICD therapy, documented sustained VT or 
VF, electrical storm, and aborted SCD). Wilcoxon’s rank sum test was used to compare the number 
of registered events before and after the ablation procedure as well as the obtained reduction in the 
number of events between patients undergoing a successful and unsuccessful procedure, 
respectively. All analyses were performed using Stata version 13.1 (StataCorp, 4905 Lakeway Dr., 
College Station, TX, USA). Two-sided p-values <0.05 were considered statistically significant. 
Results 
We included 435 patients in the study. Baseline characteristics are shown in Table 1. Mean age was 
38 years and 255 (59%) were males. Relatives accounted for 215 (49%) of the population, of which 
91 (42%) had definite ARVC. Baseline characteristics according to proband status are displayed in 
Supplementary Table 1.  
Over the time course of the study, a total of 90 VT ablation procedures were 
registered in 49 patients. Median follow-up time from inclusion was 7.9 years (IQR 4.9-12.5 years). 
The cumulative incidence of VT ablation was 11% (95%CI 8%-14%) after 10 years (Table 2 and 
Figure 1). However, all ablation procedures were performed in probands. Comparing the use of VT 
ablation among pairs of probands and their corresponding relatives matched on age and sex reduced 
the number of patients for analysis to 80, in which the likelihood of VT ablation was significantly 
higher in probands (p=0.0021). In univariate Cox regression models, male sex and ventricular 
arrhythmia at presentation were also significant predictors of the clinically considered need of VT 
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ablation. However, these associations diminished in the adjusted analyses restricted to probands, 
where only age at inclusion below the median remained significantly associated with an increased 
clinically considered need of VT ablation. 
Information on the VT ablation procedure as well as patient characteristics of the 49 
patients undergoing first-time VT ablation is shown in Table 3. The use of VT ablation among 
ARVC patients increased steadily over the years with the first registered procedure performed in 
1989 and 25 (51%) of first-time procedures performed after January 1st 2010. The number of 
procedures performed per year is displayed in Supplementary Figure 1. Median follow-up time 
from VT ablation to the first event of interest, death or censoring was 0.8 years (IQR 0.2-3.9 years). 
The cumulative risk was high in all pre-specified subgroups (Figures 2 and Table 4), but younger 
age at the time of ablation and use of antiarrhythmic drugs were associated with a higher HR of 
ventricular arrhythmias. In adjusted analyses, these factors as well as inducibility to VT 
immediately after ablation were independently associated with an unfavorable outcome.  
In 15 patients the first-time VT ablation procedure was performed within the first 6 
months of follow-up after diagnosis, whereas one patient underwent heart transplantation less than 
3 months after VT ablation. The remaining 33 patients were followed both 6 months before and 6 
months after the ablation procedure. Among these patients the median number of registered 
episodes with ventricular arrhythmias was 2 (IQR 1-3, range 0-9) during the 6 months period prior 
to the first successful VT ablation compared with 0 (IQR 0-1, range 0-7) during the first 6 months 
period after ablation (p=0.0042). There was no change in the median number of antiarrhythmic 
drugs received at time of ablation compared with 6 months after ablation (median difference: 0, 
IQR 0-0, range -1-1, p=1.00). A successful VT ablation was associated with a significant reduction 
in the number of ventricular arrhythmic episodes (Before: 2 (IQR 1-3, range 0-9) After: 0 (IQR 0-1, 
range 0-2), p=0.0003); a reduction not seen after unsuccessful procedures (Before: 1 (IQR 0-3, 
range 0-5) After: 0 (IQR 0-2, range 0-7), p=0.63) (Figure 3). However, comparing the reduction in 
the number of ventricular arrhythmic episodes between successful and unsuccessful procedures was 
not statistically significant (p=0.11).  
In sensitivity analyses we further evaluated the effect of VT ablations over time as 
well as differences between participating centers on risk of recurrent ventricular arrhythmias 
(Supplementary Material). We found no statistically significant effects of time of ablation or 
experience with VT ablation at the participating sites on ventricular arrhythmia recurrence.  
Information on VT ablation complications was available in 43 patients. Six (14%) 
patients experienced a complication, of which 3 patients developed pericardial effusion, 1 
developed embolism to the left popliteal artery, 1 developed traumatic circumflex artery injury 
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treated with percutaneous coronary intervention, and 1 patient had polymorphic incessant VT 
induced by stimulation leading to cancellation of the procedure. 
Discussion 
The present study is the first to describe the use of VT ablation in a large multi-center registry of 
patients with an ARVC diagnosis. Our study showed that 20% of ARVC probands had a clinically 
driven VT ablation performed within 10 years after presentation, whereas no mutation-carrying 
relatives underwent any procedures. After first-time VT ablation we observed a substantial risk of 
recurrent ventricular arrhythmias in all predefined subgroups, although the number of ventricular 
arrhythmic events decreased notably after ablation. This reduction in ventricular arrhythmic burden 
was particularly driven by findings in patients in whom the VT ablation procedure was categorized 
as successful. 
For the first person in a family to seek medical attention and to be diagnosed with 
ARVC (i.e. the proband) the phenotype needs to be clinically manifest. In case a pathogenic 
mutation is found, subsequent cascade screening may lead to the identification of several mutation-
carrying relatives, in whom the disease may or may not be clinically evident. Accordingly, 
probands with definite ARVC have been shown to carry an 8-fold higher risk of ventricular 
arrhythmias compared with mutation-carrying relatives.17 Although this finding may partly be 
explained by the preclinical disease state in which relatives are often diagnosed another study also 
found a higher risk of ventricular arrhythmias in probands compared with relatives even though 
both probands and relatives all had definite ARVC.18 The absence of VT ablation procedures 
among mutation-carrying relatives in our study support prior findings by indicating that treatment 
with antiarrhythmic medication and ICD therapy according to current guidelines may be sufficient 
to prevent clinically significant ventricular arrhythmias in these individuals. Although mutation-
carrying relatives a priori have a major ARVC criterion given their mutation, it is worth noting that 
2 out of 5 mutation-carrying relatives in our study fulfilled the 2010 TFC for definite ARVC at the 
time of diagnosis. Nevertheless, these patients did not undergo VT ablation, suggesting a less 
penetrant disease expression in affected relatives compared with the proband in the family. In this 
context it should be emphasized that the presence of a mutation in itself does not seem to predict 
ventricular arrhythmias in patients with definite ARVC.2 Accordingly, in the present study mutation 
status was not associated with need for VT ablation among probands with definite ARVC. 
Consequently, the identification of a disease-causing mutation in a family might be seen as a 
confirmation of monogenic ARVC rather than a marker of outcome. 
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Prior studies of patients undergoing VT ablation have shown a large variability in 
reported outcomes.3-12 In general the most promising results have been demonstrated in from high-
volume single-centers using an epicardial ablation strategy, which has been increasingly utilized 
throughout the last decade.4,5,7,10 These studies have reported VT-free survivals ranging from 91% 
after a median follow up of 11 months to 71% after 56 months.4,5,7,10 In the light of these studies it 
is rather disappointing that 3 out of 4 patients in our cohort experienced a recurrent ventricular 
arrhythmia within 5 years. One explanation may be the continuing evolution of mapping and 
ablation techniques over the time course of the study, and therefore, these results might not reflect 
success rates currently achieved. However, we did not find evidence of improved outcomes over 
time, despite ventricular arrhythmic burden after ablation seemed to be more markedly reduced in 
later years. Furthermore, we were not able to demonstrate superiority of an epicardial or combined 
ablation approach, although it should be emphasized that only 16% of procedures used an epicardial 
access, which may in part explain the disappointing efficacy. Consequently, our results may reflect 
the general outcome expected after VT ablation among unselected ARVC patients seen in the broad 
daily clinical practice.  
The major strength of our study includes the long-term follow-up on a large 
multinational cohort of patients with ARVC. However, our study has several limitations. The study 
was based on registry data from a large registry on ARVC, which does not contain detailed data on 
indications for VT ablation, mapping techniques, ablation procedures, or VT morphologies. The 
different TFC criteria used prior to and after 2010 might have caused a slightly different selection 
of patients over time. Also, since data prior to the launch of the registry in 2010 were based on 
retrospectively collected data from medical files there is a chance that clinically insignificant VT 
episodes have been underreported. However, we found the risk of recurrent ventricular arrhythmias 
to be similarly high in both time periods. Some patients (in particular the very elderly) may have 
been considered ineligible for VT ablation. Although this is likely not the case for the vast majority 
of the population, there is a potential risk of an indication bias slightly influencing the estimates. 
The rate of procedures at each center was relatively low in light of the long-term follow-up and the 
number of participating centers. Consequently, it might be possible that a higher experience with 
VT ablation in ARVC patients at the participating centers would have improved outcome after 
ablation. Over the course of the study guidelines and treatment protocols have changed. Hence, the 
results reflect those averaged over time and may not reflect current regimens. In order for a patient 
to be candidate for VT ablation, a ventricular arrhythmia needs to be present before but not after the 
time of the procedure. Therefore, some of the reduction in the ventricular arrhythmic burden may 
potentially be explained by a natural fluctuation in the VT burden over time giving rise to an 
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overestimation of the effect of VT ablation. In the multivariable cox regression models the number 
of predictor variables was relatively high compared to the number of events giving rise to a 
potential risk of over-fitting the models. To address this issue we performed additional sensitivity 
analyses including each covariate one at a time. These results proved to be very similar to the 
reported results, which were also supported by the relative similarities between crude and adjusted 
analyses.  
In conclusion, probands diagnosed with ARVC carry a high risk of future need for VT 
catheter ablation whereas mutation-carrying relatives seem to be without such need. This may 
suggest a favorable prognosis among relatives in which standard care, comprising close monitoring 
and possibly ICD- and AAD therapy, may be sufficient to protect these individuals from recurrent 
ventricular arrhythmias. In probands undergoing VT ablation the post-procedural arrhythmic burden 
was reduced but risk of recurrent ventricular arrhythmias remained substantial. 
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Figure 1. Cumulative incidence of VT catheter ablation stratified by subgroups 
Cumulative incidence functions calculated with death and heart transplantation as competing risks. 
A: All patients. B-F: Stratified by subgroups. 
 
Figure 2. Cumulative risk of recurrent ventricular arrhythmias after first-time VT 
catheter ablation 
Cumulative risk of ventricular arrhythmias including ventricular tachycardia (VT), ventricular 
fibrillation (VF), electrical storm and sudden cardiac death. Non-sudden cardiac death, non-cardiac 
death, and heart transplantation were taken into account as competing risks. A: All patients. B-F: 
Stratified by subgroups. AAD = antiarrhythmic drug. 
 
Figure 3. Burden of ventricular arrhythmias before and after VT catheter ablation 
Number of VT/VF in patients with ≥6 months follow-up before (blue) and after (red) VT catheter 
ablation, stratified in successful (A) and unsuccessful (B) procedures. VT/VF include registered 
episodes of ventricular tachycardia (VT), ventricular fibrillation (VF), and electrical storm. 
 
